MilliporeSigma, the life science business of Germany-based Merck KGaA, reports that it is investing €35 million ($37 million) in biosafety testing at its Glasgow and Stirling sites in Scotland. The ...
MilliporeSigma, the U.S. and Canada life science business of Merck KGaA, Darmstadt, Germany, has opened its new $286 million biosafety testing facility in Rockville. Biosafety testing and analytical ...
Facility consolidates biosafety testing, analytical development, and cell bank manufacturing services into single building New rapid test offering with Blazar ® CHO Animal Origin Free (AOF) delivers ...
MilliporeSigma, Merck KGaA’s life science business, opened the second phase of its new €29 million ($31.7 million) Biologics Testing Center in China, adding 1,500 m 2 to the lab opened last year.
Since the beginning of the COVID-19 pandemic, PCR assays have been the gold standard for detecting SARS-CoV-2. Mammoth Biosciences (CA, USA) is developing a CRISPR-based diagnostic workflow that aims ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results